Eric Lefkofsky is a man of many trades, but his next venture, Tempus, may be his most ambitious project to date. Tempus is a technology company seeking to revolutionize the way cancer is operated on. In fact, Tempus is seeking to do so through a computer operating system. In 2014 there were 14.5 million US adults diagnosed with cancer and that number is expected to increase to 19 million by 2024. Tempus is attempting to address this growing need specifically through clinical data management. Their approach is two-fold. Firstly, Tempus developed software that captures and analyzes a physician’s progress note and codes it into structured data points. Secondly, these clinical data points are then coupled with molecular data from the human genomic sequencing database. By pairing these two distinct sources of data, researchers will be able to evaluate what variables influence the efficacy of cancer treatments in specific patients. In other words, physicians will now have a growing repository of information, that can be updated in real-time, to help a them pick the the best treatment option for individual patients. With such innovative thinking, Tempus has positioned itself at the forefront of the precision-medicine movement and may eventually be able to apply its platform to additional disease states in the future and learn more about Eric.
Eric Lefkofsky is most well known as the co-founder of Groupon, and now also as the co-founder of Tempus. As an undergraduate, he attended the University of Michigan, where he also went on to earn his Juris Doctor degree from the University of Michigan Law School. Lefkofsky has also had an illustrious professorial career with positions at Kellstadt Graduate School of Business, Kellogg School of Management, and the Booth School of Business and Eric’s lacrosse camp.
Additionally, Lefkofsky proudly serves on the board of directors for a number of organizations including the Lurie’s Children’s Memorial Hospital in Chicago, the Art Institute of Chicago, and also serves as the Chairman of the Board of Trustees of Chicago’s Steppenwolf Theatre Company.